Automated Summary
Key Facts
Zyla Life Sciences sued Wells Pharma of Houston under state laws in California, Colorado, Connecticut, Florida, South Carolina, and Tennessee that prohibit selling unapproved new drugs. Wells Pharma, a registered compounding facility, sells non-FDA-approved indomethacin suppositories. The district court dismissed Zyla's claims, ruling the state laws were preempted by federal law, but the Fifth Circuit reversed, holding state laws mirroring the FDCA's requirements are not preempted under the 'Zook' doctrine.
Issues
The central issue is whether state laws that mirror federal requirements (specifically, prohibitions on selling unapproved new drugs under the FDCA) are preempted when they incorporate those federal standards. The court held that such laws do not create a conflict with federal law because they 'make federal law their own,' aligning with precedent in California v. Zook and rejecting arguments that parallel enforcement disrupts federal objectives.
Holdings
- The district court's denial of Zyla's motion for leave to amend was vacated. The appellate court remanded the case for further proceedings consistent with its opinion.
- The court held that state laws incorporating federal requirements under the FDCA are not preempted by conflict preemption, as they do not create an obstacle to federal objectives. The state laws align with federal law and 'make federal law their own,' eliminating any conflict.
- Wells Pharma's cross-appeal regarding attorney's fees was dismissed as moot. The court determined that the appeal's outcome rendered the fee dispute irrelevant.
- The district court's order granting Wells Pharma's motion to dismiss was reversed. The appellate court concluded that the state laws do not conflict with the FDCA and that the district court erred in dismissing Zyla's claims.
Remedies
- Wells Pharma's cross-appeal of the denial of its motion for an award of attorney's fees is DISMISSED AS MOOT.
- The district court's order granting Wells Pharma's motion to dismiss is REVERSED.
- The case is REMANDED for further proceedings consistent with this opinion.
- The district court's order denying Zyla's motion for leave to amend is VACATED.
Legal Principles
The court applied the principle that state laws mirroring federal law are not preempted under the Supremacy Clause when there is no conflict. This was based on precedent like California v. Zook, which held that identical state and federal laws do not create a conflict. The opinion also referenced Wyeth v. Levine to affirm concurrent state and federal regulation of drug safety. Additionally, it distinguished Buckman Co. v. Plaintiffs' Legal Committee, which involved state-law claims against federal agency fraud and was deemed preempted, from the current case where state enforcement of mirrored federal standards was permitted.
Precedent Name
- Buckman Co. v. Plaintiffs' Legal Committee
- Wyeth v. Levine
- California v. Zook
- Kansas v. Garcia
- Houston v. Moore
Cited Statute
- Federal Food, Drug, and Cosmetic Act
- Colorado Revised Statutes
- Tennessee Code
- California Health & Safety Code
- Connecticut General Statutes
- South Carolina Code
- Florida Statutes
Judge Name
- Ho
- Oldham
- Duncan
Passage Text
- The question presented is whether a State triggers implied obstacles-and-purposes preemption when it expressly incorporates federal law into state law. The district court held yes. But as the Supreme Court held almost a century ago, 'there is no conflict in terms, and no possibility of such conflict, for the state statute makes federal law its own.' California v. Zook, 336 U.S. 725, 735 (1949). Therefore, we reverse.
- The Supreme Court held that the California law was not preempted. The mere 'fact of identity,' the Court explained, did 'not mean the automatic invalidity of State measures.' Id. at 730. On the contrary, there was 'no conflict in terms, and no possibility of such conflict, for the state statute ma[de] federal law its own.' Id. at 735; see also Garcia, 589 U.S. at 212 ('[T]here is no basis for inferring that federal statutes preempt state laws whenever they overlap.') Since there was no conflict, the state statute was not preempted.
- Congress did not regard state tort litigation as an obstacle to achieving its purposes. Its silence on the issue, coupled with its certain awareness of the prevalence of state tort litigation, is powerful evidence that Congress did not intend FDA oversight to be the exclusive means of ensuring drug safety and effectiveness.